Camila Batista Daniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camila Batista Daniel has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Priscila Marinho de Abreu
Biotechnology Post-Graduation Program, Health Sciences Center, Federal University of Espírito Santo, Vitória 29040-090, Espírito Santo, Brazil
3 shared publications - Sandra Ventorin von Zeidler
Pathology Department, Federal University of Espírito Santo, Vitória, Brazil
3 shared publications - Agenor Sena
Head and Neck Surgery Division, Santa Rita de Cássia Hospital, Vitória 29043-260, Espírito Santo, Brazil
1 shared publication - Brena Ramos Athaydes
Postgraduate Program in Biotechnology, Health Sciences Center, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil
1 shared publication - Brena Ramos Athaydes
Biotechnology Post-Graduation Program, Health Sciences Center, Federal University of Espírito Santo, Vitória 29040-090, Espírito Santo, Brazil
1 shared publication - Enes Buck Mutiua Cantala Xavier
Faculty of Health Sciences, Zambeze University, Beira 2300, Mozambique
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3557
Low HPV16 E6 Seroprevalence in HNSCC: A Prospective Study in Brazil
Background/Objectives: Head and neck squamous cell carcinoma (HNSCC) remains a global public health challenge with significant morbidity and mortality. Emerging epidemiological data indicate a rising global incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). Serology for early HPV antigens has been highlighted as a relevant biomarker for HPV-associated OPSCC. This study aimed to determine the seroprevalence of HPV16 E6 antibodies in HNSCC patients in the state of Espírito Santo, Brazil. Methods: This is a prospective longitudinal cohort study in which 287 patients with HNSCC were enrolled, recruited from two oncology centers in Espírito Santo between 2011 and 2018, along with 68 cancer-free individuals. Serum samples were analyzed using the HPV16 E6 GST Capture ELISA assay. Statistical analysis was performed using SPSS. Binary logistic regression was employed to identify independent predictors of seropositivity. Results: The overall seroprevalence of HPV16 E6 antibodies was 7.3%. Seropositivity was observed in tumors of the oral cavity (6.2%) and oropharynx (13.3%). Patients with OPSCC demonstrated a significantly higher likelihood of seropositivity compared to those with tumors of the oral cavity, larynx, and hypopharynx (OR = 2.96, 95% CI: 1.21–7.28, p = 0.018). The highest frequency of HPV16 E6-positive cases occurred in tumors of the palatine tonsils (OR = 6.00; 95% CI: 1.58–22.89; p < 0.009). No seropositive cases were observed in hypopharyngeal or laryngeal tumors. Among patients with OPSCC and oral cavity squamous cell carcinoma (OCSCC), HPV16 E6 serostatus did not significantly correlate with sociodemographic, behavioral, or clinical tumor characteristics. Conclusions: Our findings reinforce the predilection of HPV-associated carcinogenesis for the oropharynx, more specifically in the palatine tonsils. In addition, this study highlights HPV16 E6 serology as a potential biomarker for HPV-driven OPSCC and underscores Brazil’s epidemiological heterogeneity, warranting standardized clinical validation.
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3557
Open AccessLow HPV16 E6 Seroprevalence in HNSCC: A Prospective Study in Brazil
Background/Objectives: Head and neck squamous cell carcinoma (HNSCC) remains a global public health challenge with significant morbidity and mortality. Emerging epidemiological data indicate a rising global incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). Serology for early HPV antigens has been highlighted as a relevant biomarker for HPV-associated OPSCC. This study aimed to determine the seroprevalence of HPV16 E6 antibodies in HNSCC patients in the state of Espírito Santo, Brazil. Methods: This is a prospective longitudinal cohort study in which 287 patients with HNSCC were enrolled, recruited from two oncology centers in Espírito Santo between 2011 and 2018, along with 68 cancer-free individuals. Serum samples were analyzed using the HPV16 E6 GST Capture ELISA assay. Statistical analysis was performed using SPSS. Binary logistic regression was employed to identify independent predictors of seropositivity. Results: The overall seroprevalence of HPV16 E6 antibodies was 7.3%. Seropositivity was observed in tumors of the oral cavity (6.2%) and oropharynx (13.3%). Patients with OPSCC demonstrated a significantly higher likelihood of seropositivity compared to those with tumors of the oral cavity, larynx, and hypopharynx (OR = 2.96, 95% CI: 1.21–7.28, p = 0.018). The highest frequency of HPV16 E6-positive cases occurred in tumors of the palatine tonsils (OR = 6.00; 95% CI: 1.58–22.89; p < 0.009). No seropositive cases were observed in hypopharyngeal or laryngeal tumors. Among patients with OPSCC and oral cavity squamous cell carcinoma (OCSCC), HPV16 E6 serostatus did not significantly correlate with sociodemographic, behavioral, or clinical tumor characteristics. Conclusions: Our findings reinforce the predilection of HPV-associated carcinogenesis for the oropharynx, more specifically in the palatine tonsils. In addition, this study highlights HPV16 E6 serology as a potential biomarker for HPV-driven OPSCC and underscores Brazil’s epidemiological heterogeneity, warranting standardized clinical validation.
- Open Access
- 6 March 2025
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 71 (2)
Management and Prognosis of Head and Neck Cancer Patients during the COVID-19 Pandemic
Introduction: The COVID-19 pandemic raised the necessity to implement measures for managing patients with head and neck squamous cell carcinoma (HNSCC). Objective: To evaluate the measures adopted by an oncological hub during the COVID-19 pandemic and investigate whether the SARS-CoV-2 infection and viral load changed the outcomes of head and neck cancer patients. Method: Patients were tested for SARS-CoV-2 using real-time quantitative reverse transcription polymerase chain reaction and rapid COVID-19 antigen testing before surgery between October 2020 and November 2021. Clinical outcomes were compared by the presence of SARS-CoV-2 infection, considering prognostic factors for HNSCC patients, such as preexisting comorbidities and tumor staging. Results: Of the 194 patients recruited, 99 cases confirmed diagnoses of HNSCC and underwent surgical treatment. The most frequent comorbidities were arterial hypertension and diabetes mellitus. The oral cavity and larynx were the most affected anatomical sites, 51% and 33%, respectively. A total of 61.6% of the cases were classified as T3/T4 and 53.4% did not have lymph node involvement. Presence of comorbidities and lymph node metastasis were associated with reduced survival. Of the 99 cases confirmed, 8.1% (8/99) were infected with SARS-CoV-2, but no differences in overall survival according to SARS-CoV-2 infection (p = 0.086) were noticed and the viral load was not associated with vital status (p = 0.456). Conclusion: The presence of SARS-CoV-2 infection did not influence overall survival in head and neck SCC patients. This is the first study to describe these findings in an oncological care center in the State of Espírito Santo, Brazil.
- 6 March 2025
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 71 (2)
Open AccessManagement and Prognosis of Head and Neck Cancer Patients during the COVID-19 Pandemic
Introduction: The COVID-19 pandemic raised the necessity to implement measures for managing patients with head and neck squamous cell carcinoma (HNSCC). Objective: To evaluate the measures adopted by an oncological hub during the COVID-19 pandemic and investigate whether the SARS-CoV-2 infection and viral load changed the outcomes of head and neck cancer patients. Method: Patients were tested for SARS-CoV-2 using real-time quantitative reverse transcription polymerase chain reaction and rapid COVID-19 antigen testing before surgery between October 2020 and November 2021. Clinical outcomes were compared by the presence of SARS-CoV-2 infection, considering prognostic factors for HNSCC patients, such as preexisting comorbidities and tumor staging. Results: Of the 194 patients recruited, 99 cases confirmed diagnoses of HNSCC and underwent surgical treatment. The most frequent comorbidities were arterial hypertension and diabetes mellitus. The oral cavity and larynx were the most affected anatomical sites, 51% and 33%, respectively. A total of 61.6% of the cases were classified as T3/T4 and 53.4% did not have lymph node involvement. Presence of comorbidities and lymph node metastasis were associated with reduced survival. Of the 99 cases confirmed, 8.1% (8/99) were infected with SARS-CoV-2, but no differences in overall survival according to SARS-CoV-2 infection (p = 0.086) were noticed and the viral load was not associated with vital status (p = 0.456). Conclusion: The presence of SARS-CoV-2 infection did not influence overall survival in head and neck SCC patients. This is the first study to describe these findings in an oncological care center in the State of Espírito Santo, Brazil.
- 18 October 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102687
Head and neck cancer mortality trends in Espírito Santo, Brazil
- 18 October 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102687
Head and neck cancer mortality trends in Espírito Santo, Brazil